This study was conducted (1) to identify prognostic factors of survival and acute leukemia evolution in a series of Korean patients diagnosed as having MDS in a single institute, (2) to apply ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, and safety of azacitidine are reviewed. Summary: Azacitidine is the first drug in a new class of compounds, ...

Authors acknowledge that both the 2022 World Health Organization and International Consensus Classification myelodysplastic syndrome criteria sets have value, while sorting out their similarities and ...

After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the ...

•Genomic characterization determines diagnosis, classification, and prognostication of the myeloid malignancies myelodysplastic syndrome (MDS) and AML. •Recognizing genetic lesions as invariable ...

—Classifying myelodysplastic syndrome and secondary acute myeloid leukemia by genetic mutations rather than strictly by blast count may allow more patients to be eligible for AML and MDS clinical ...

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (Nasdaq:CELG - News) today announced VIDAZA (azacitidine) received expanded U.S. Food and Drug Administration (FDA) approval to reflect new overall ...

Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. To determine the treatment outcome of ...

These MDS FAB subtypes include according to the French American British (FAB classification: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia ...

The classification system for this type of cancer aims to help define, diagnose, and treat the disease and improve outcomes. Myelodysplastic syndromes (MDSs), which are now also called myelodysplastic ...